67be8235-7f6f-4c36-9ad7-c72f8308fb52
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 73.6262833675565
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.560
- ANGIOGENESIS+0.470
- TGF_BETA_SIGNALING+0.460
- HEDGEHOG_SIGNALING+0.390
- UV_RESPONSE_DN+0.370
- TNFA_SIGNALING_VIA_NFKB+0.330
- KRAS_SIGNALING_UP+0.300
- APICAL_JUNCTION+0.290
- COAGULATION+0.290
- WNT_BETA_CATENIN_SIGNALING+0.290
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.600
- FATTY_ACID_METABOLISM-0.420
- ADIPOGENESIS-0.370
- E2F_TARGETS-0.360
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.330
- DNA_REPAIR-0.320
- GLYCOLYSIS-0.280
- XENOBIOTIC_METABOLISM-0.240
- PROTEIN_SECRETION-0.220
- PEROXISOME-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 21196229-e39e-4846-be58-a1055b3ae50e | — | — | 0.882 |
| 2 | 3fcb923c-5dd2-4d6f-a6bb-8074ffb762be | — | — | 0.882 |
| 3 | TCGA-C8-A132-01A-31R-A115-07 | — | C | 0.877 |
| 4 | ec054d40-e5b8-496a-8c99-5e7f88f2cf37 | — | — | 0.864 |
| 5 | SRR15069613 | — | — | 0.861 |
| 6 | f22cfa82-a346-4fed-bc81-21a29bf990ee | — | — | 0.858 |
| 7 | SRR25043621 | — | — | 0.855 |
| 8 | 1b5aacb8-0e2e-4888-bc61-48c4aa4d4684 | — | — | 0.850 |
| 9 | a307b24f-4caa-403a-8313-2a4604f2079a | — | — | 0.849 |
| 10 | SRR25043620 | — | — | 0.848 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.560 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.470 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.460 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.390 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.370 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.330 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.290 | Inavolisib | — uncovered |
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.290 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.250 | Inavolisib | — uncovered |
| APOPTOSIS | 0.230 | Idelalisib | — uncovered |
| MYOGENESIS | 0.230 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.210 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.210 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.150 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.140 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.130 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.130 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.110 | Cobimetinib | — uncovered |